The Grand Cascadia Ballroom shimmered under a canopy of crystal chandeliers, casting soft golden light over the gathering of scientists, doctors, and survivors. The plush, deep-blue carpet muffled the sound of hurried footsteps as attendees took their seats at round tables, each adorned with sleek nameplates and crisp white linens. At the front of the room, a long table sat elevated on a stage, where the panelists—those who had fought diseases firsthand and those who had waged war against them in laboratories and hospitals—were ready to begin.

  Dr. Evelyn Carter adjusted her glasses and tapped the microphone. “Good evening, everyone. Welcome to the Global Infectious Disease Summit. We’re here to bridge the gap between research and real-life survival, to understand not just the science, but the human stories behind these diseases.” She nodded towards a man sitting beside her. “Mr. Daniel Ng, would you share your experience with us?”

  Daniel, his voice steady but eyes shadowed by memory, leaned forward. “I was diagnosed with drug-resistant tuberculosis while working as a journalist abroad. At first, I thought it was just a persistent cough. It took months to get the right treatment, and there were moments when I thought I wouldn’t make it. The isolation was brutal. But the doctors who stuck with me, who didn’t give up, are the reason I’m here today.”

  A murmur ran through the audience before Dr. Amir Patel, an epidemiologist, chimed in. “Daniel’s story highlights the very real challenge of resistant strains. We have treatments, but they are grueling. And if we don’t find better solutions, we’ll be facing an untreatable epidemic in the near future.”

  Across the panel, a woman named Lucia Torres took the microphone next. “I survived Ebola,” she said, her voice tinged with both pride and sorrow. “I lost my sister to it, though. The worst part was watching her go and knowing there was nothing I could do.”

  Dr. Carter placed a hand over Lucia’s. “You fought through it. And the antibodies in your blood helped develop better treatments.”

  Lucia nodded. “That’s why I’m here. We can’t just be victims—we have to be part of the solution.”

  A young researcher, Dr. Marcus Feldman, stood up from the audience. “The survivors are teaching us so much. We’re seeing how some immune systems respond better, and that’s shaping new therapies. But the biggest challenge? Access. We can have the best treatments in the world, but if they don’t reach the people who need them…”

  Dr. Patel sighed. “Politics, infrastructure, funding—it all plays a role. Science alone won’t save us. We need policy, global cooperation, and the voices of people like Daniel and Lucia to remind the world what’s at stake.”

  The room fell into a contemplative silence before Dr. Carter smiled. “That’s why we’re here. To listen, to learn, and to act. Let’s continue the conversation.”

  This story is posted elsewhere by the author. Help them out by reading the authentic version.

  The audience erupted in applause, and as the panelists exchanged glances, there was a shared understanding—this was more than just a conference. It was a call to arms.

  But beyond the polished discussions and warm rhetoric, a darker reality lurked. Across the globe, those with the rare genetic markers and antibodies that made them resilient to these diseases found themselves in sterile labs, their blood drawn again and again. Officially, they were 'doing their part'—heroes in the fight against pandemics. But in truth, they were little more than glorified lab rats, their existence reduced to data points and test subjects for the next great pharmaceutical breakthrough.

  It had started voluntarily. People were convinced to enlist in the program, believing they were contributing to the greater good. But when volunteers dwindled, the program changed. Suddenly, extra blood was being drawn at routine check-ups, even from children. And then, one by one, they began to disappear.

  The narrative remained pristine—these individuals were selflessly offering themselves to science. s showcased their ‘noble sacrifice,’ with smiling faces and carefully curated testimonies. But behind closed doors, a dystopian truth emerged. Those with genetic resilience to disease were no longer seen as people, but as resources. Scientists and corporate executives spoke of them in terms of 'yield' and 'viability,' their existence reduced to genetic material waiting to be harvested.

  Families who asked too many questions found themselves under scrutiny. Records vanished, and official explanations ranged from medical complications to sudden relocations. Whispers spread in hushed tones—whole communities where children with exceptional immune systems had simply ceased to exist. Hospitals, once places of healing, became points of extraction. Bloodwork that should have been routine became something more sinister, the first step in a quiet but relentless culling.

  News outlets, initially enamored with the scientific breakthroughs, started questioning the disappearances. Investigative journalists uncovered inconsistencies in hospital records and testimonies from grieving families whose loved ones had never come home. Leaked documents from whistleblowers painted a chilling picture—a program that had shifted from voluntary participation to covert abduction.

  The outcry was immediate. Survivors like Daniel and Lucia, once hailed as champions of medical progress, found themselves at the center of a terrifying truth. “We were celebrated for what made us different,” Daniel said in an emotional interview. “Now that same difference is being used to justify our erasure.”

  Governments scrambled to reassure the public. Official statements dismissed the claims as conspiracy theories, but the evidence continued to mount. Secret research facilities were uncovered, their sterile halls lined with refrigerated storage units labeled not with names, but with genetic codes. People who had trusted the system, who had given their blood willingly, were nothing more than test subjects.

  Protests erupted worldwide, demanding justice for the disappeared. Some survivors went into hiding, fearing they were next. “We thought we were helping humanity,” Lucia whispered in a leaked video message. “But humanity betrayed us.”

  Despite the backlash, the program did not end. It simply adapted. New incentives were introduced, targeting those in poverty with promises of financial security in exchange for ‘routine medical participation.’ The narrative remained unchanged—the world still needed its survivors.

  And as the conference came to a close, as the panelists shook hands and the audience filed out, the truth loomed over them all. Humanity’s best hope for survival had become its most exploited resource, and few dared to ask—who would be next?